Alumis Inc Common Stock
Price & Volume
Stats
See moreOpen | $4.39 |
Previous Close | $4.34 |
Day Range | $4.35-$4.65 |
52W Range | $2.76-$13.11 |
Market Cap | $443.7M |
Shares Short | 3M |
Financials
See moreRevenue (12 Mos) | $17.3M |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $17.3M |
Diluted EPS | -$11.24 |
News
See moreYahoo Finance • 7 days ago
TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight
Yahoo Finance • 20 days ago
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
Yahoo Finance • 29 days ago
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
Yahoo Finance • 2 months ago
Alumis to Present at the Jefferies Global Healthcare Investor Conference
About
CEO | Mr. Martin Babler Ph.D. |
Address | 280 East Grand Avenue, South San Francisco, CA, United States, 94080 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 182 |
